CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor
Kwonoh Park, Jae-Lyun Lee, Jin-Hee Ahn, Kyoo Hyung Lee, In-Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn
Cancer Research and Treatment. 2014;46(4):339-347.   Published online 2014 July 16    DOI: https://doi.org/10.4143/crt.2013.154

Excel Download

Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor
Cancer Research and Treatment. 2014;46(4):339-347   Crossref logo
Link1 Link2

Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
BMC Cancer. 2013;13(1):   Crossref logo
Link1 Link2 Link3

Everolimus in Patients with Metastatic Renal Cell Carcinoma Who Progress after Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFR-TKI) Therapy: UK Results from the react Trial on Behalf of the UK React Investigators
Annals of Oncology. 2012;23:ix271-ix272   Crossref logo
Link1 Link2

Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor
International Journal of Urology. 2014;21(7):740-740   Crossref logo
Link1 Link2

Editorial Comment to Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor
International Journal of Urology. 2014;21(7):741-741   Crossref logo
Link1 Link2

83 International, expanded-access programme of everolimus in patients with metastatic renal cell carcinoma who progressed after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: Sub-analysis of European patients
European Urology Supplements. 2012;11(1):e83-e83a   Crossref logo
Link1 Link2

725 SEQUENTIAL USE OF MTOR -INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT
European Urology Supplements. 2011;10(2):231   Crossref logo
Link1 Link2

95 SEQUENTIAL USE OF TEMSIROLIMUS (TEM) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT
European Urology Supplements. 2010;9(2):63   Crossref logo
Link1 Link2

Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
Cancer Chemotherapy and Pharmacology. 2015;75(5):1025-1035   Crossref logo
Link1 Link2 Link3

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
Yearbook of Urology. 2007;2007:127-129   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.